Jake Van Naarden
Executive Vice President And President, Lilly Oncology And Head Of Corporate Business Development
Eli Lilly and Company · LLY
$7.6M
Reported total · FY2025 · SCT Total as filed
Source: DEF 14A filed March 20, 2026. Prior years are from that filing's three-year table.
Catalog as of September 15, 2026. Not a live market feed.
- Salary
- $920K
- Stock Awards
- $6.5M
- Other
- $160K
Compensation History
| Fiscal Year | Salary | Stock Awards | Total Compensation |
|---|---|---|---|
| 2025 | $920,192 | $6,506,019 | $7,586,097 |
| 2024 | $890,385 | $4,703,614 | $5,773,948 |
| 2023 | $830,769 | $3,927,892 | $4,886,520 |
Current Position
- Company
- Eli Lilly and Company
- Title
- Executive Vice President And President, Lilly Oncology And Head Of Corporate Business Development
- Ticker
- LLY · NYSE
- Fiscal Year
- 2025
SEC Sources
Fiscal years below are columns from the latest DEF 14A Summary Compensation Table (filed March 20, 2026), not separate historical filings.
| Fiscal Year | Source |
|---|---|
| 2025 | View SEC filing |
| 2024 | View SEC filing |
| 2023 | View SEC filing |
Accession 0000059478-26-000029.
Other Eli Lilly Executives
David A. Ricks
Chair, President, And Chief Executive Officer
Eli Lilly · LLY
$36.7M
FY 2025 · DEF 14A
Lucas Montarce
Executive Vice President And Chief Financial Officer
Eli Lilly · LLY
$8.5M
FY 2025 · DEF 14A
Daniel M. Skovronsky
M.D., Ph.d. Executive Vice President, Chief Scientific And Product Officer And President, Lilly Research Labs
Eli Lilly · LLY
$17.8M
FY 2025 · DEF 14A
Anat Hakim
Executive Vice President, General Counsel And Secretary
Eli Lilly · LLY
$9.8M
FY 2025 · DEF 14A